T2 Biosystems, Inc.
TTOO · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $7 | $22 | $28 | $18 |
| % Growth | -67.8% | -20.5% | 54.8% | – |
| Cost of Goods Sold | $15 | $21 | $21 | $21 |
| Gross Profit | -$8 | $1 | $7 | -$3 |
| % Margin | -113.6% | 5.2% | 26.2% | -17.4% |
| R&D Expenses | $14 | $26 | $22 | $17 |
| G&A Expenses | $0 | $31 | $0 | $0 |
| SG&A Expenses | $25 | $31 | $29 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $0 | $0 | $0 |
| Operating Expenses | $41 | $57 | $50 | $38 |
| Operating Income | -$50 | -$54 | -$43 | -$41 |
| % Margin | -690.4% | -242.3% | -153.2% | -228.1% |
| Other Income/Exp. Net | -$0 | -$7 | -$6 | -$5 |
| Pre-Tax Income | -$50 | -$62 | -$49 | -$47 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$50 | -$62 | -$49 | -$47 |
| % Margin | -696.2% | -278% | -175.5% | -258.1% |
| EPS | -19.19 | -1,222.14 | -1,549.82 | -1,928.54 |
| % Growth | 98.4% | 21.1% | 19.6% | – |
| EPS Diluted | -19.19 | -1,222.14 | -1,549.82 | -1,928.54 |
| Weighted Avg Shares Out | 3 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 3 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5 | $6 | $8 | $6 |
| Depreciation & Amortization | $1 | $1 | $3 | $3 |
| EBITDA | -$44 | -$55 | -$41 | -$37 |
| % Margin | -610% | -246% | -146.6% | -202.5% |